NCT07390578

Upneeq vs. Lumify Ptosis

Comparative Effect of Oxymetazoline 0.1% (Upneeq) and Brimonidine 0.025% (Lumify) on Upper Eyelid Position in Acquired Ptosis: A Randomized, Double-Masked, Crossover Study

• Status: Not Yet Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Duke University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aims to compare the short-term effect of oxymetazoline 0.1% (Upneeq) versus brimonidine 0.025% (Lumify) on upper-eyelid position in adults with acquired ptosis. Participants will undergo standardized eyelid photography, receive a single dose of either Upneeq or Lumify in randomized order, and have repeat photographs approximately 60 minutes later. They will return for a second visit to receive the alternate medication using the same procedures. Eyelid height measurements will be obtained from coded images by masked graders. Data will be analyzed using paired statistical methods appropriate for a crossover design. Both medications are FDA-approved topical ophthalmic drops, and the study involves minimal risk with anticipated transient ocular irritation as the most common adverse event.

Conditions

• Acquired Ptosis

Interventions

Type	Name	Description
DRUG	Oxymetazoline 0.1% (Upneeq)	Single instillation of oxymetazoline 0.1% ophthalmic solution in both eyes.
DRUG	Brimonidine 0.025% (Lumify)	Single instillation of brimonidine 0.025% ophthalmic solution in both eyes.

Timeline

• Start date: 2026-03-01
• Primary completion: 2026-08-01
• Completion: 2026-12-01
• First posted: 2026-02-05
• Last updated: 2026-02-05

Regulatory

• FDA-regulated drug study